Header Logo

Connection

C OSBORNE to Prognosis

Back to Details
This is a "connection" page, showing publications C OSBORNE has written about Prognosis.
C OSBORNE
Connection Strength
0.480
Prognosis
  1. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
    View in: PubMed
    Score: 0.026
  2. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40.
    View in: PubMed
    Score: 0.020
  3. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
    View in: PubMed
    Score: 0.018
  4. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998 Jan; 4(1):7-12.
    View in: PubMed
    Score: 0.018
  5. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998; 51(3):227-38.
    View in: PubMed
    Score: 0.018
  6. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat. 1997 May; 44(1):65-74.
    View in: PubMed
    Score: 0.017
  7. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
    View in: PubMed
    Score: 0.014
  8. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994 May 04; 86(9):705-12.
    View in: PubMed
    Score: 0.014
  9. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74.
    View in: PubMed
    Score: 0.014
  10. Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat. 1994; 32(1):105-12.
    View in: PubMed
    Score: 0.014
  11. Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994; 32(1):67-71.
    View in: PubMed
    Score: 0.014
  12. A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Ann Oncol. 2013 Jan; 24(1):47-53.
    View in: PubMed
    Score: 0.012
  13. Prognostic factors in breast cancer. Semin Oncol. 1992 Jun; 19(3):244-53.
    View in: PubMed
    Score: 0.012
  14. Prognostic factors for breast cancer: have they met their promise? J Clin Oncol. 1992 May; 10(5):679-82.
    View in: PubMed
    Score: 0.012
  15. Polypeptide growth factors: their potential value in the management of breast cancer patients. Cancer Treat Res. 1992; 60:315-29.
    View in: PubMed
    Score: 0.012
  16. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29; 9(1):16-32.
    View in: PubMed
    Score: 0.012
  17. Prognostic factors in breast cancer. Hematol Oncol Clin North Am. 1989 Dec; 3(4):641-52.
    View in: PubMed
    Score: 0.010
  18. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol. 2009 Oct 20; 27(30):4973-9.
    View in: PubMed
    Score: 0.010
  19. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15; 15(16):5258-66.
    View in: PubMed
    Score: 0.010
  20. Adjuvant therapy in node-negative breast cancer. A panel discussion. Breast Cancer Res Treat. 1989 Mar; 13(2):97-115.
    View in: PubMed
    Score: 0.010
  21. Cell proliferative indices and DNA content as prognostic factors in primary breast cancer. Horm Res. 1989; 32 Suppl 1:238-41.
    View in: PubMed
    Score: 0.010
  22. Adjuvant treatment of node-negative breast cancer. Tex Med. 1989 Jan; 85(1):32-6.
    View in: PubMed
    Score: 0.010
  23. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.
    View in: PubMed
    Score: 0.008
  24. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
    View in: PubMed
    Score: 0.008
  25. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
    View in: PubMed
    Score: 0.008
  26. Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. J Am Vet Med Assoc. 2005 Feb 01; 226(3):393-400.
    View in: PubMed
    Score: 0.007
  27. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9.
    View in: PubMed
    Score: 0.007
  28. Hormone receptors in the management of breast cancer. Tex Med. 1984 Nov; 80(11):30-2.
    View in: PubMed
    Score: 0.007
  29. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9.
    View in: PubMed
    Score: 0.007
  30. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 03; 349(1):17-26.
    View in: PubMed
    Score: 0.007
  31. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003 May 15; 21(10):1973-9.
    View in: PubMed
    Score: 0.006
  32. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003 May 15; 63(10):2434-9.
    View in: PubMed
    Score: 0.006
  33. Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis. Adv Exp Med Biol. 1981; 138:377-85.
    View in: PubMed
    Score: 0.005
  34. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15; 46(12 Suppl):2884-8.
    View in: PubMed
    Score: 0.005
  35. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res. 2000 Feb; 6(2):616-21.
    View in: PubMed
    Score: 0.005
  36. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999 Oct; 17(10):3058-63.
    View in: PubMed
    Score: 0.005
  37. Therapy for cancer of the breast. Current status of steroid hormone receptors. West J Med. 1979 May; 130(5):401-7.
    View in: PubMed
    Score: 0.005
  38. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999 May; 17(5):1442-8.
    View in: PubMed
    Score: 0.005
  39. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999 May; 17(5):1474-81.
    View in: PubMed
    Score: 0.005
  40. The use of stero?d hormone receptors in the treatment of human breast cancer: a review. Bull Cancer. 1979; 66(3):203-9.
    View in: PubMed
    Score: 0.005
  41. Current use of steroid hormone receptor assays in the treatment of breast cancer. Surg Clin North Am. 1978 Aug; 58(4):777-88.
    View in: PubMed
    Score: 0.005
  42. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998 Apr 01; 82(7):1296-302.
    View in: PubMed
    Score: 0.005
  43. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
    View in: PubMed
    Score: 0.004
  44. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997 Dec 17; 89(24):1874-81.
    View in: PubMed
    Score: 0.004
  45. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8.
    View in: PubMed
    Score: 0.004
  46. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr; 43(2):153-63.
    View in: PubMed
    Score: 0.004
  47. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996 Nov; 14(11):3009-17.
    View in: PubMed
    Score: 0.004
  48. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
    View in: PubMed
    Score: 0.004
  49. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92.
    View in: PubMed
    Score: 0.004
  50. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.
    View in: PubMed
    Score: 0.004
  51. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 03; 85(3):200-6.
    View in: PubMed
    Score: 0.003
  52. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992 Sep; 23(9):974-9.
    View in: PubMed
    Score: 0.003
  53. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol. 1992 Mar; 10(3):428-32.
    View in: PubMed
    Score: 0.003
  54. Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). J Natl Cancer Inst Monogr. 1992; (11):167-72.
    View in: PubMed
    Score: 0.003
  55. The role of growth factors in breast cancer. A panel discussion. Breast Cancer Res Treat. 1988 Oct; 12(2):159-66.
    View in: PubMed
    Score: 0.002
  56. Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. Cancer Res. 1988 Sep 01; 48(17):5023-8.
    View in: PubMed
    Score: 0.002
  57. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987 Jan; 5(1):55-61.
    View in: PubMed
    Score: 0.002
  58. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984 Oct; 2(10):1102-9.
    View in: PubMed
    Score: 0.002
  59. Steroid hormone receptors in the management of human breast cancer. Ann Clin Res. 1980 Oct; 12(5):202-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.